SINO BIOPHARM: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025

Sino Biopharm announced its performance for the first half of 2025, reporting a year-on-year revenue increase of 10.7% to RMB 17.57 billion, with a gross margin up 0.4 percentage points to 82.5%. The financial statements indicated that the profit attributable to owners of the parent company from continuing operations was approximately RMB 3.39 billion, a year-on-year increase of 140.2%. The Board declared an interim dividend of HKD 0.05 per share. During the period, revenue from innovative products reached RMB 7.8 billion, representing a year-on-year increase of 27.2% and accounting for 44.4% of total revenue. Research and development expenditures were approximately RMB 3.19 billion, accounting for 18.1% of revenue. The company obtained approval for two innovative products during the period, namely Purtanib (Meloxicam Injection) and Anqixin (Recombinant Human...Show More

Sino Biopharm announced its performance for the first half of 2025, reporting a year-on-year revenue increase of 10.7% to RMB 17.57 billion, with a gross margin up 0.4 percentage points to 82.5%. The financial statements indicated that the profit attributable to owners of the parent company from continuing operations was approximately RMB 3.39 billion, a year-on-year increase of 140.2%. The Board declared an interim dividend of HKD 0.05 per share. During the period, revenue from innovative products reached RMB 7.8 billion, representing a year-on-year increase of 27.2% and accounting for 44.4% of total revenue. Research and development expenditures were approximately RMB 3.19 billion, accounting for 18.1% of revenue. The company obtained approval for two innovative products during the period, namely Purtanib (Meloxicam Injection) and Anqixin (Recombinant Human Coagulation Factor VIIa for Injection N01). The company continues to advance its internationalization strategy, announcing in July the acquisition of Lixin Pharmaceutical for USD 500 million, further enhancing its core competitiveness in the field of oncology innovation. The company anticipates that nearly 20 innovative products will be approved for market launch over the next three years, with more than half expected to exceed RMB 2 billion in peak sales. By the end of 2027, the company expects the number of launched innovative products to exceed 35, with innovative product revenue accounting for more than 60% of total revenue.